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Special issue on mitogen-activated protein kinases: New insights into
regulation, function and role in human diseaseThe mitogen-activated protein kinase (MAPK) signaling
pathways have been extensively studied for the past 20 years,
establishing their key roles in numerous cellular functions and
founding a model signaling pathway system. Of special
significance was the early recognition of their involvement in
various human cancers, prompting a concerted effort to identify
inhibitors along the pathway as potential cancer therapeutics.
Currently there are several lead compounds in clinical trials that
target various MAPK pathways, predominantly Raf, MLK and
MEK inhibitors. Although remarkable progress has been made
in understanding various aspects of MAPK function and
regulation, many other remain poorly understood. These aspects
include among others the physiological effects of MAPKs under
normal cell growth conditions, during development, in cell
cycle regulation and with respect to distinct cell type functions.
Other pressing questions relate to defining the exact molecular
aspects of their regulation, defining the cross-talk relationships
between the various MAPK pathways and better defining their
downstream targets. Furthermore, the extensive incorporation
of inhibitors of MAPK pathways in clinical trials and potentially
in the near future in the clinic calls for ways to better evaluate
the data coming from clinical trials to help in designing future
targets and approaches to improving treatment efficacy. The aim
of this MAPKs-dedicated special issue is to provide a
comprehensive and up-to-date review of the field while
underlining the remaining questions and gaps in our under-0167-4889/$ - see front matter © 2007 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbamcr.2007.03.005standing. In addition, a special focus is given to the role of
MAPKs in various pathologies and our perceptions regarding
the targeting of these pathways for therapy.
The first part of this issue provides a historical overview of
the field and introduces the classical Ras-Raf-MEK-ERK
MAPK pathway, covering the pathway from the receptor level
to ERKs and their targets. The second part focuses on aspects of
MAPK regulation by phosphatases and through cross-talk
mechanisms and addresses clinical aspects and other emerging
novel concepts. The third part covers physiological aspects of
MAPK function and also includes an overview of yeast
MAPKs. The final part covers the so-called stress-activated
MAPK pathways and includes a review of atypical MAPKs.
Obviously, not all aspects of this diverse field could be
addressed in one issue, and we extend our apologies to the many
contributors to this field whose work was not covered.
I thank all the authors who contributed to this issue and the
reviewers for the highly constructive and helpful comments.
Special thanks to Joseph Avruch for the constant encourage-
ment and valuable advice. Finally, thanks to the BBA editorial
office for the continuous and skilled support.
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